Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Unknown 3Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 20Rectal Neoplasms 12Colonic Neoplasms 11Head and Neck Neoplasms 6Neoplasm Metastasis 5Carcinoma, Hepatocellular 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Neoplasms 3Keratosis, Actinic 3Esophageal Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Skin Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Nasopharyngeal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms 2Adenocarcinoma Of Esophagus 2Tongue Neoplasms 1Recurrence 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Motor Activity 1Melanoma 1Malignant Tumor of Pancreas Metastatic to Liver 1Lymphoma, Non-Hodgkin 1

Interventions

Dexamethasone 14Rituximab 6Cytarabine 5venetoclax 4Lenalidomide 4Bortezomib 4Bendamustine Hydrochloride 4selinexor 3pomalidomide 3pembrolizumab 3ibrutinib 3fludarabine 3carfilzomib 3Paclitaxel 3Gemcitabine 3Drug Therapy 3Cyclophosphamide 3Calcium Dobesilate 3ixazomib 2gilteritinib 2fludarabine phosphate 2elotuzumab 2daratumumab 2belinostat 2Tablets 2Surveys and Questionnaires 2Panobinostat 2Oxaliplatin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Recurrence × Fluorouracil × Clear all
NCT00386516 2017-08-01

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

Galectin Therapeutics Inc.

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Gallbladder Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡